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Resveratrol is a bioactive polyphenol, found in grapes, red wine, and peanuts, and has recently garnered much
media and scientific attention for its diverse beneficial health effects as a nutritional supplement or nutraceutical.
Of particular interest are the well-documented cardioprotective effects of resveratrol that are mediated by diverse
mechanisms, including its antioxidant and vascular effects. However, it is now becoming clear that resveratrol may
also exhibit direct effects on cardiac function and rhythm through modulation of signaling pathways that regulate
cardiac remodeling and ion channel activity that controls cardiac excitability. Resveratrol may therefore possess
antiarrhythmic properties that contribute to the cardiovascular benefits of resveratrol. Atrial fibrillation (AF) is the
most common cardiac arrhythmia, although current therapies are suboptimal. Our laboratory has been studying
resveratrol’s effects on cardiac ion channels and remodeling pathways, and we initiated a drug development program
aimed at generating novel resveratrol derivatives with improved efficacy against AF when compared to currently
available therapeutics. This review therefore focuses on the effects of resveratrol and new derivatives on a variety
of cardiac ion channels and molecular pathways that contribute to the development and maintenance of atrial
fibrillation.
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Atrial fibrillation: a major health concern
with suboptimal treatment
Atrial fibrillation (AF) is the most common type of
cardiac electrical rhythm disturbance, and the inci-
dence of AF is increasing in most developed coun-
tries as a result of the aging population.1–4 While AF
does not generally induce sudden cardiac death, AF
is the primary cause of 15% of strokes5,6 and can
also cause adverse remodeling of the heart leading
to heart failure (HF).1,5,7,8 Furthermore, 30–40%
of patients undergoing coronary artery bypass graft
(CABG) surgery develop transient postoperative AF
that may develop into permanent AF.9 While direct
current cardioversion (DCC) remains the standard
of care for AF, there are associated risks and costs
associated with this procedure, DCC is not always
successful,10 and not all centers can perform DCC
within an adequate time frame.
In addition, the prevalence of AF increases with
age, with 0.5% of patients affected in the 50-year-
old range and 10% over the age of 80,11 and the
prediction is that it will increase in the future.12 HF
and AF are often diagnosed in the same patient, and
those with HF are more likely to develop AF com-
pared to the general population.13 The presence of
AF in HF patients with either preserved or reduced
left ventricular function carries an increased risk for
all-cause mortality.14 In patients with HF or AF, the
development of the other condition leads to further
deterioration of an already poor prognosis. The
analysis of the relationship of AF andHF in patients
from the FraminghamHeart Study revealed that, in
patients with HF, later development of AF was asso-
ciated with increased mortality in both sexes.13 As
such, AF andHFwere called the “twonew epidemics
of cardiovascular disease.”15 Many underlying dis-
eases are common risk factors for both HF and
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AF, including hypertension, valvular heart disease,
coronary artery disease, and diabetes.16 These
conditions, either collectively or individually, may
eventually lead to structural and electrophysiolog-
ical remodeling17 and sustained neurohormonal
activation that promote the development of AF and
HF.18 Once established, AF can promote HF owing
to rapid ventricular rate, leading to tachycardia-
induced cardiomyopathy and associatedmyocardial
maladaptive remodeling.19 Therefore, early thera-
peutic interventions to reduce AF may also reduce
the burden of the more serious disease of HF.
However, despite the increasing burden of AF
and its association with HF, current pharma-
cotherapy for the prevention and treatment of AF
still has major limitations,3,4 and relies on either
(1) rate control with -blockers, glycosides, and
calcium channel antagonists,20,21 or (2) rhythm
control2,21 using either class I antiarrhythmics,
such as propafenone and fleciainide, or class III
antiarrhythmics, such as amiodarone, dronedarone,
and dofetilide. The multichannel inhibitor amio-
darone is the most effective, orally bioavailable
drug; however, its use is limited by its very long
half-life, negative drug–drug interactions, severe
extracardiac side effects, and significant risk for
acquired long-QT (LQT) syndrome and torsade de
pointes arrhythmias.22,23 Dronedarone, an analogue
of amiodarone, was designed to have an improved
pharmacokinetic and safety profile; however, the
recent PALLAS trial evaluating dronedarone in
patients with permanent AF (>7 days) was stopped
prematurely owing to a lack of efficacy in converting
permanent AF and increasing heart failure events.24
In addition, dronedarone was found to increase
mortality in patients with significantly reduced left
ventricular function in HF in the ANDROMEDA
trial.25
Vernakalant (BrinavessTM), a multi-ion channel
blocker developed by Cardiome Pharma Corp., is
currently the only atrial-selective antiarrhythmic
drug approved for IV use in Europe,26,27 although
it has not been approved in North America.
Although only 50% of patients are responsive to
vernakalant,28 it is nevertheless the best-in-class AF
IV therapeutic currently available for the manage-
ment of acute AF.Until recently, an oral formulation
of vernakalant was being developed in partnership
with Merck; however, further development was
discontinued in March 2012. It was reported that
this decision was based upon “Merck’s assessment
of the regulatory environment and projected
development timeline.” As such, there is still a large
unmet need for the development of improved oral
antiarrhythmic compounds for AF29 that are also
atrial specific and exhibit few side effects.30
Cellular etiology of AF and potential
drug targets
In an attempt to maintain proper cardiac function
and intracellular homeostasis in response to patho-
physiological processes involved in cardiovascular
diseases, includingHF andAFdevelopment, a num-
ber of electrophysiological and structural changes
occur in the heart, collectively described as myocar-
dial remodeling.1,17,31 These alterations are partly
adaptive in nature; however, when maintained for
longer periods they can lead to further deterioration
of cardiac function resulting in HF, and can also sig-
nificantly contribute to the development and main-
tenance of ventricular and atrial arrhythmias such
as AF. Over the last decade, the cellular mechanisms
underlying AF have been extensively investigated
and include alterations in ion channel expression
and chronic activation of signaling pathways con-
trolling cellular remodeling.
Improved knowledge of the mechanisms under-
lying AF represents a key opportunity to develop
novel atrial-specific therapies for the treatment of
AF, and, in this regard, several promising thera-
peutic targets have been revealed for potential drug
development. One important atrial-specific target
is the Kv1.5 (IKur), a potassium channel expressed
in the atria, but not the ventricles.32 In addition
to Kv1.5, late sodium current (late INa),33 overac-
tive IKACh channels,32,34,35 inflammation/oxidative
stress,36 and activation of the nuclear factor of acti-
vated T cells (NFAT)37 have all been implicated in
the development of AF.
Therefore, on the basis of the available informa-
tion, an ideal multifunctional small molecule drug
for AF should possess the following properties: (1)
frequency-dependent Kv1.5 inhibition, (2) late INa
inhibition, (3) IKACh channel inhibition, (4) lack of
hERG channel inhibition to reduce the likelihood
of drug-induced LQT syndrome,38 (5) atrial speci-
ficity, (6) antioxidant properties, and (7)NFAT inhi-
bition. The complex etiology of AF and themultiple
mechanisms responsible for the development and
maintenance of AF led to the suggestion that novel
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compounds targeting several pathways involved in
AF may exhibit improved efficacy.29,39
Resveratrol: a parent molecule for AF
drug design?
Since reports of the “French paradox” came to
light,40–42 suggesting red wine consumption as
beneficial to cardiovascular health, there have been
numerous studies on the polyphenolic constituents
of red grape products.43,44 It is now clear that
resveratrol (3,5,4′-trihydroxy-trans-stilbene) is
one of several bioactive polyphenols that may be
potentially harnessed for the treatment of many
diseases including cardiovascular disease.43,45,46 In
addition, when given orally, resveratrol is remark-
ably well tolerated and exhibits very few side effects,
which collectively contribute to its popularity as a
nutritional supplement.47 However, more human
data are required from well-executed clinical trials,
as much of the evidence fueling resveratrol’s fame
comes from preclinical data from rodents.45,46,48
Translation of the effects of resveratrol observed in
preclinical animal studies into humans therefore
remains a challenge.49,50
Through intense research efforts, resveratrol has
been shown to exhibit pharmacological activity
against many diverse cellular signaling pathways in
a wide range of tissues that are involved in dis-
eases that include cancer, aging-related degenera-
tive diseases, inflammation, cardiovascular disease,
obesity, and diabetes.46,51 With respect to the direct
effects of resveratrol on the heart, previous stud-
ies have already demonstrated the beneficial effects
of resveratrol against HF52 and ventricular arrhyth-
mias in the setting of ischemia/reperfusion injury53
in rodents. Moreover, a recent study has shown that
resveratrol reduces AF susceptibility in the failing
heart via the PI3K/Akt/eNOS signaling pathway.54
With respect to remodeling in AF, the rapidly
contracting atria may lead to imbalances in calcium
homeostasis and subsequent calcium loading that
lead to chronic activation of the calcium-sensitive
phosphatase calcineurin.37,55,56 NFAT dephospho-
rylation by calineurin allows its activation and
translocation into the nucleus to activate a pro-
hypertrophic gene transcription program in the
heart.57–59 Such transcriptional activity likely con-
tributes to marked alterations in the gene profiles
of atria from patients with AF.60 Notably, resver-
atrol has been shown to inhibit this hypertrophic
cardiac remodeling process via activation of AMP-
activated kinase (AMPK) and subsequent inhibition
of NFAT activation,61,62 which has been implicated
in the development of AF,37 pathological cardiac
hypertrophy, and HF.52,57
In addition to resveratrol’s ability to beneficially
alter cardiac structural and electrical remodeling in
the setting of hypertrophy,HF, andAF, this polyphe-
nol also exerts a direct effect on several cardiac ion
channels that are responsible for the maintenance
and propagation of the cardiac action potential
that forms the basis of appropriate electrical activ-
ity and correct excitation–contraction coupling. In
particular, inhibition of late INa has emerged as
a potential therapeutic strategy for the treatment
of ischemia/reperfusion injury,63 HF, and AF.33
In this regard, several studies have indicated that
inhibitory effects of resveratrol and derivatives on
voltage-gated sodium channels contributed to their
antiarrhythmic actions. With respect to late INa,
resveratrol inhibited H2O2-induced augmentation
of late INa in rat ventricularmyocytes9 and inhibited
oxidative stress–induced arrhythmogenic activity in
rabbit ventricular myocytes through inhibition of
late INa. However, these studies did not separate the
antioxidant effects of resveratrol from any direct
effects on late INa. In this respect, our group previ-
ously published a comprehensive study of the direct
effects of several polyphenols on human voltage-
gated sodium currents.64 In contrast to lidocaine,
resveratrol did not exhibit any frequency depen-
dence of the peak INa block, although late INa,
induced by the long-QT mutant R1623Q or the sea
anemone toxin ATX II, was reduced by resveratrol.
In field-stimulated ventricular myocytes, ATXII-
induced increases in diastolic calcium concentra-
tion and contractile dysfunction were prevented
and reversed by resveratrol.64 These data support
the concept that resveratrol has a direct inhibitory
effect on late INa that results in reduced electrical
andcontractile dysfunction.Collectively, these stud-
ies indicate that resveratrol inhibits several path-
ways involved in the development of AF, although
we found that resveratrol is a poor inhibitor of
the atrial-specific Kv1.5 potassium channel (IC50 =
66 M) that is a major potential therapeutic target
for AF.32
On the basis of this evidence of the potential for
multifunctional biological activity of resveratrol in
HF and AF, we speculated that nature may already
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Figure 1. Chemical structures of resveratrol and compound 1
(C1).
have provided an ideal starting template for rational
drug design of novel AF therapeutics. Therefore, our
group initiated a drug development program, using
resveratrol as the parent compound, in an attempt
to optimize its Kv1.5 and IKACh inhibitory pro-
file while maintaining antioxidant and NFAT/late
INa inhibitory efficacy. Accordingly, we synthesized
several compounds by combining resveratrol with
a known Kv1.5 inhibitor AVE0118 and identified
a novel compound (compound 1, C1, (Fig. 1)).
C1 dose-dependently inhibited peak and late Kv1.5
(IC50 = 0.36 and 0.11 M, respectively), IKACh
(IC50 = 1.9 M), peak INa, and late INa (IC50 = 3.0
and 1 M, respectively). C1 also displayed marked
frequency-dependent Kv1.5 inhibition and was a
much more potent inhibitor at stimulation rates
of 3 Hz compared to 1 Hz.65 Collectively, such an
ionic pharmacological profile may serve to prevent
either adverse action potential shortening through
increased Kv1.5 or IKACh activity or excessive action
prolongation through induction of late INa, result-
ing in maintenance of the action potential duration
(APD) in an optimal range to reduce the occurrence
of AF (Fig. 2).
With respect to nonionic effects, C1 also demon-
stratedNFAT-inhibitory and antioxidant properties
that were similar to those of the parent molecule
resveratrol.65 This effect is likely owing to activation
of AMPK that suppresses NFAT activation and is
a known target of the parent molecule resveratrol,
although the effects of C1 on AMPK remain to be
tested experimentally. Although the effects of C1
on structural remodeling and fibrosis remain to be
tested experimentally, resveratrol has been shown
to markedly reduce cardiac fibrosis in a rat model
of pressure-overload hypertrophy.66 It has also been
demonstrated that resveratrol may impart some of
its cardioprotective effects through inhibition of
the renin–angiotensin system,67 and this possibility
remains to be explored with respect to resveratrol
and C1 in the setting of AF.
With reference to nonatrial effects, C1 displayed
no effects on calcium handling or contractility in
isolated ventricular myocytes, suggesting that, at
concentrations effective at modulating atrial ion
channels, C1 will have little effect on ventricular
excitation–contracting coupling in ventricular tis-
sue, although any effects on calcium handling in
atrial tissue remain to be determined. These results
indicated that C1 may possess beneficial and atrial-
specific antiarrhythmic properties for AF. To test
this notion, we used an atrial tachypacing–induced
canine AF model and found that C1 was effective at
reducing the onset and duration of AF episodes at
a dose of 1 mg/kg (I.V. bolus), which resulted in a
blood plasma concentration of1 M.65
Importantly, C1 showedonlyweakhERGchannel
inhibition (IC50 = 30 M), displaying 100-fold
selectivity for Kv1.5 inhibition over hERG. More-
over, C1 did not prolong the QT interval in
conscious dogs, suggesting that the compound did
not significantly influence ventricular repolariza-
tion and was unlikely to provoke long QT–induced
and torsade de pointes ventricular arrhythmias at
the concentrations tested in these experiments. A
conclusion, based on these effects, is that C1 holds
promise as a multifunctional small molecule by
Figure 2. Proposed cellular mechanisms of action for the anti-AF effects of resveratrol derivatives such as C1.
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targeting several key pathways known to be involved
in the development andmaintenance of AF (Fig. 2).
Future directions
There are several major hurdles to overcome in
the design of orally available small molecules for
long-term prophylactic therapy, such as achieving
adequate absorption and resistance to metabolic
degradation/modification, that collectively con-
tribute to prolonged circulating plasma levels of
an effective dose of the biologically active drug.
However, as a parent molecule, resveratrol is not
an ideal starting compound in these respects. For
example, although resveratrol is well absorbed
through the gut wall, it is rapidly metabolized
into by-products and metabolites or cleared in the
urine.68–70 Therefore, the effective concentrations
and half-life of unmodified resveratrol in the plasma
are very low, with the half-life being measured
at 49 min in healthy volunteers.69,71 As such, the
pharmacokinetic profile of resveratrol is not ideally
suited to pharmacological development, although
this may be enhanced significantly through
formulation.71 Nevertheless, resveratrol itself is a
naturally occurring polyphenol with few side effects
that shows great promise as a parent molecule for
the design of much needed novel drugs for the
treatment of AF, and efforts are underway in our
laboratory to strike the delicate balance between
improving the biological activity of resveratrol
derivatives with respect to multiple AF targets while
improving upon the suboptimal pharmacokinetics
observed in the parent resveratrol molecule. In the
meantime, human trials on the effects of resveratrol
for the prevention of AF should be pursued,
especially in the more controlled acute setting
of elective cardiac surgery such as CABG, where
postoperative AF occurs in 30–40% of patients.9
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